Capricor Therapeutics (CAPR) Net Margin (2016 - 2024)
Historic Net Margin for Capricor Therapeutics (CAPR) over the last 16 years, with Q4 2024 value amounting to 24.29%.
- Capricor Therapeutics' Net Margin fell 174400.0% to 24.29% in Q4 2024 from the same period last year, while for Sep 2025 it was 199.26%, marking a year-over-year decrease of 785800.0%. This contributed to the annual value of 100.9% for FY2024, which is 121400.0% down from last year.
- According to the latest figures from Q4 2024, Capricor Therapeutics' Net Margin is 24.29%, which was down 174400.0% from 555.2% recorded in Q3 2024.
- Capricor Therapeutics' 5-year Net Margin high stood at 6.86% for Q4 2023, and its period low was 23187.59% during Q3 2020.
- Moreover, its 5-year median value for Net Margin was 477.75% (2022), whereas its average is 3521.29%.
- Its Net Margin has fluctuated over the past 5 years, first crashed by -220567500bps in 2020, then skyrocketed by 45047700bps in 2021.
- Quarter analysis of 5 years shows Capricor Therapeutics' Net Margin stood at 7224.51% in 2020, then soared by 66bps to 2482.54% in 2021, then surged by 68bps to 800.77% in 2022, then skyrocketed by 99bps to 6.86% in 2023, then tumbled by -254bps to 24.29% in 2024.
- Its last three reported values are 24.29% in Q4 2024, 555.2% for Q3 2024, and 276.97% during Q2 2024.